Core Viewpoint - Hainan Haiyao's subsidiary has received approval for a new chemical drug, indicating potential growth in its pharmaceutical portfolio and market presence [1] Group 1: Company Developments - Hainan Haiyao's wholly-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., has obtained the Drug Registration Certificate for "Fumaric Acid Vonoprazan Tablets" from the National Medical Products Administration [1] - The registered indication for the drug is gastroesophageal reflux disease, which can be used in conjunction with appropriate antibiotics to eradicate Helicobacter pylori [1]

Core Viewpoint - Hainan Haiyao's subsidiary has received approval for a new chemical drug, indicating a positive development in its product pipeline and potential market expansion [1] Group 1 - The company announced that its wholly-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., has obtained the Drug Registration Certificate for "Fumaric Acid Vonoprazan Tablets" from the National Medical Products Administration [1] - The registered indication for the drug is gastroesophageal reflux disease, which is a significant condition that affects many patients [1] - The drug is intended to be used in conjunction with appropriate antibiotics to eradicate Helicobacter pylori, a common bacterial infection linked to various gastrointestinal diseases [1]

证券代码：000566 证券简称：海南海药 公告编号：2025-066 海南海药股份有限公司 关于子公司获得富马酸伏诺拉生片药品注册批件的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）全资子公司海口市制药厂有限 公司近日获得国家药品监督管理局核准签发的化学药品"富马酸伏诺拉生片"的 《药品注册证书》。现将相关情况公告如下： 一、产品基本情况 1、药品名称：富马酸伏诺拉生片 剂型：片剂 规格：10mg、20mg 受理号：CYHS2401390、CYHS2401391 注册分类：化学药品 4 类 适应症：反流性食管炎。与适当的抗生素联用以根除幽门螺杆菌。 药品上市许可持有人：海口市制药厂有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 2、药品的其他相关情况 富马酸伏诺拉生是一款钾离子竞争性酸阻滞剂（P-CAB），与传统的质子泵 抑制剂（PPI）相比，伏诺拉生具有更快的起效速度、更长的作用时间和更强的 抑制胃酸分泌效果。目前富马酸伏诺拉生 ...

Core Viewpoint - Hainan Haiyao's stock price has shown a significant increase this year, with a 25.47% rise, despite a recent decline over the past 60 days [1][2] Group 1: Stock Performance - As of October 31, Hainan Haiyao's stock price reached 6.01 CNY per share, with a market capitalization of 7.797 billion CNY [1] - The stock has experienced a 5.07% increase over the last five trading days and a 9.07% increase over the last 20 trading days, while it has decreased by 6.39% over the last 60 days [1] - The company has appeared on the stock market's "龙虎榜" three times this year, with the latest occurrence on June 3 [1] Group 2: Financial Performance - For the period from January to September 2025, Hainan Haiyao reported a revenue of 640 million CNY, representing a year-on-year decrease of 20.51%, while the net profit attributable to shareholders was -242 million CNY, showing a year-on-year increase of 17.91% [2] - The company has cumulatively distributed 466 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3] Group 3: Shareholder Information - As of October 20, the number of shareholders for Hainan Haiyao increased by 4.70% to 77,500, while the average number of circulating shares per person decreased by 4.49% to 15,040 shares [2] - As of September 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 6.6464 million shares, a decrease of 1.1481 million shares from the previous period [3]

Group 1 - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for any false records or misleading statements [2][10][29] - The third-quarter financial report has not been audited [9][10] - The company has received cash of 33.19 million yuan and has 101 sets of commercial housing registered under its name as part of debt compensation [6][7] Group 2 - The company has initiated legal proceedings against Southern Tongzheng and Hainan Haiyao Real Estate for failure to repay debts, with a court ruling requiring payment of approximately 311.17 million yuan and 200.45 million yuan in principal and penalties [7][8] - The company will hold its fifth extraordinary general meeting on November 18, 2025, to discuss various proposals, including amendments to the articles of association and the establishment of a new governance structure [11][35][36] - The board of directors has approved the adjustment of the special committee members to enhance governance efficiency [30][31][32]

证券代码：000566 证券简称：海南海药 公告编号：2025-064 海南海药股份有限公司 关于修订<公司章程>的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（下称"公司"）根据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司章程指引》等有关法律法规、深圳证券交易所 的相关规定，结合公司实际情况和经营发展需要，公司拟对《公司章程》部分条 款进行修订。本次修订后的《公司章程》需经公司股东大会审议通过后方可生效。 修改后的《公司章程》经股东大会审议通过后，公司将不再设监事会，原监 事会将停止履职，监事自动解任,《监事会议事规则》相应废止，公司各项制度 中涉及监事会、监事的规定不再适用。公司对各位监事在任职期间做出的贡献表 示诚挚的感谢。 在本次修订过程中，除对比表所示修订内容外，公司另根据《公司法》《上 市公司章程指引（2025 年修订）》等法律法规和规范性文件，将《公司章程》全 文的"股东大会"表述修改为"股东会"；同时统一表述，将阿拉伯数字统一为 中文，将"或"统一为"或者"。如因增加、删除、排列某些章节、条款导致章 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-065 海南海药股份有限公司 关于召开 2025 年第五次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2025 年第五次临时股东大会 2、股东大会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法 律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 7、出席对象： （1）在股权登记日持有公司股份的普通股股东或其代理人。 于 2025 年 11 月 11 日下午收市时，在中国证券登记结算有限责任公司深圳分公司登 记在册的全体普通股股东均有权出席股东大会。股东可以书面委托代理人出席会议和参加 表决（该股东代理人不必是公司的股东）。 （2）公司董事、监事和高级管理人员。 （3）公司聘请的律师。 （4）根据相关法规应当出席股东大会的其他人员。 4、会议时间： （1）现场会议时间：2025 年 11 月 1 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-062 海南海药股份有限公司 第十一届董事会第二十八次会议决议公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）第十一届董事会第二十八次会 议于 2025 年 10 月 29 日以通讯表决方式召开。本次会议于 2025 年 10 月 27 日以 电子邮件等方式送达了会议通知及文件。会议应到董事 9 人，实到董事 9 人，会 议的召开符合《公司法》和《公司章程》有关规定。经与会董事认真审议，表决 通过了如下议案： 一、 审议通过了《2025 年第三季度报告的议案》 具体内容详见同日刊载于巨潮资讯网（www.cninfo.com.cn）的《海南海药 股份有限公司 2025 年第三季度报告》。 表决结果：9 票同意，0 票反对，0 票弃权 二、审议通过了《关于调整第十一届董事会专门委员会委员的议案》 为进一步优化公司治理架构，提升决策科学性与治理效能，根据《公司章程》、 董事会各专门委员会议事规则的有关规定，董事会对四个专门委员会成员进行调 整，董事会各专门委员 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥189,408,874.14, a decrease of 10.36% compared to the same period last year[5] - The net profit attributable to shareholders was -¥84,000,150.87, with a year-to-date loss of -¥242,307,257.15[5] - The basic and diluted earnings per share were both -¥0.0647 for the current period[5] - Total operating revenue for the current period is CNY 639,683,832.92, a decrease of 20.5% compared to CNY 804,727,228.88 in the previous period[21] - The company reported a net loss of ¥262,645,523.82 for the current period, compared to a net loss of ¥313,678,925.17 in the previous period, representing an improvement of approximately 16.3%[22] - Operating profit (loss) for the current period was ¥-258,156,904.69, compared to ¥-305,059,177.96 in the previous period, indicating a reduction in losses by about 15.3%[22] - The company’s total comprehensive loss for the current period was ¥263,166,228.46, compared to a loss of ¥314,027,001.89 in the previous period, showing an improvement of about 16.3%[22] - Basic and diluted earnings per share were both reported at ¥-0.1868, an improvement from ¥-0.2275 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,790,095,764.09, down 5.29% from the end of the previous year[5] - The equity attributable to shareholders decreased by 47.01% to ¥278,371,317.30 compared to the previous year-end[5] - Current liabilities increased to CNY 4,359,829,200.30 from CNY 4,299,131,641.34, indicating a rise of 1.4%[19] - The company's total liabilities decreased to CNY 5,467,732,524.80 from CNY 5,523,151,531.94, a decrease of 1.0%[19] - The company's cash and cash equivalents decreased to CNY 259,728,662.81 from CNY 329,624,399.72, a decline of 21.1%[18] - Long-term equity investments slightly decreased to CNY 422,800,067.93 from CNY 429,519,914.71, a reduction of 1.6%[18] Cash Flow - Cash flow from operating activities for the year-to-date was ¥25,873,667.52, showing a significant improvement from -¥67,262,673.90 in the same period last year[9] - Cash flow from operating activities generated a net inflow of ¥25,873,667.52, a significant recovery from a net outflow of ¥67,262,673.90 in the previous period[23] - The company received cash from financing activities amounting to ¥2,303,823,616.13, compared to ¥3,048,072,741.84 in the previous period, reflecting a decrease of approximately 24.4%[24] - The company’s cash outflow from investing activities was ¥117,272,070.86, slightly down from ¥129,324,421.62 in the previous period[23] Expenses - Research and development expenses decreased by 52.86% to ¥27,335,705.41 compared to the previous year[9] - Sales expenses were reduced by 44.45% to ¥113,371,830.98, indicating effective control over market development costs[9] - The company's research and development expenses decreased to CNY 27,335,705.41 from CNY 57,982,852.49, a reduction of 52.9%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 74,037[11] - The largest shareholder, Hainan Huadong Industrial Co., Ltd., holds 22.89% of shares, totaling 296,989,889 shares, with 148,494,944 shares pledged[11] - Shenzhen Nanfang Tongzheng Investment Co., Ltd. holds 10.28% of shares, totaling 133,346,318 shares, with 130,825,900 shares frozen[11] - Yunnan International Trust Co., Ltd. holds 5.26% of shares, totaling 68,295,512 shares[11] Legal and Financial Obligations - The company is pursuing legal action against Southern Tongzheng and others for a total debt of 311,169,942.04 RMB plus interest[15] - The company has a total of 101 properties mortgaged as collateral, with priority after certain banks[14] - The company has signed multiple agreements regarding debt transfer and compensation since December 2020[16] Other Financial Metrics - The company reported a significant increase in other payables by 75.84% to ¥1,898,667,712.80, primarily due to financial support from the controlling shareholder[9] - The company recorded a net investment income of ¥6,038,962.20, a recovery from a loss of -¥50,014,917.00 in the previous year[9] - The company's net investment income is CNY 6,038,962.20, a significant recovery from a loss of CNY 50,014,917.00 in the previous period[21] - The total assets decreased to CNY 5,790,095,764.09 from CNY 6,113,528,499.69, representing a decline of 5.3%[20] - The company's other comprehensive income after tax attributable to the parent company was ¥-520,704.64, compared to ¥-348,076.72 in the previous period, indicating a decline in comprehensive income[22]

Core Viewpoint - Hainan Haiyao reported a decline in revenue and significant net losses for the third quarter and the first three quarters of the year [1] Financial Performance - The company's revenue for the third quarter was 189 million, a year-on-year decrease of 10.36% [1] - The net loss for the third quarter amounted to 84 million [1] - For the first three quarters, the total revenue was 640 million, reflecting a year-on-year decline of 20.51% [1] - The net loss for the first three quarters reached 242 million [1]